Covered recipient · General Payments record
NOLAN JACKSON BEAVERS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,499.22
- Reported across 162 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $282.05 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $93.26 | 5 |
| Mylan Specialty L.P. | $29.50 | 2 |
| DEXCOM, INC. | $20.56 | 1 |
| Teva Pharmaceuticals USA, Inc. | $19.98 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $19.81 | 1 |
| Neurocrine BioSciences, Inc. | $18.57 | 1 |
| Lilly USA, LLC | $17.57 | 1 |
| Amgen Inc. | $17.02 | 1 |
| Novo Nordisk AS | $16.18 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 1 |
| Electromed, Inc. | $14.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.12 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103296668 | CMS |
| ABBVIE INC. | $23.98 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103296670 | CMS |
| ABBVIE INC. | $16.61 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103296672 | CMS |
| ABBVIE INC. | $21.93 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103296674 | CMS |
| ABBVIE INC. | $16.62 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103296676 | CMS |
| Amgen Inc. | $17.02 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115443957 | CMS |
| Boston Scientific Corporation | $19.81 | 03/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092579665 | CMS |
| Dexcom, Inc. | $20.56 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153326139 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101848064 | CMS |
| Electromed, Inc. | $14.18 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137879748 | CMS |
| Lilly USA, LLC | $17.57 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135251910 | CMS |
| Mylan Specialty L.P. | $13.80 | 04/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147352432 | CMS |
| Mylan Specialty L.P. | $15.70 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147287332 | CMS |
| Neurocrine Biosciences, Inc. | $18.57 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150863647 | CMS |
| Novo Nordisk Inc | $16.18 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097351120 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.98 | 07/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151576697 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.